TQ Quiz | Pharmaceutical Update Innovations and Insights for Eye Care (Amsterdam 2026)

"*" indicates required fields

Quiz

This field is hidden when viewing the form

Date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event Date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event 90 days past date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event Date Difference (Hidden)

1. In the Pharmaceutical Resource Matrix, who is the best resource to discuss questions about off-label pharmaceutical use?*

A - Local sales representative

B - Regional sales representative

C - National sales representative

D - Medical science liaison

2. When it comes to total tear capacity, what is the capacity for topical medication?*

A - 10 microliters

B - 30 microliters

C - 50 microliters

D - 70 microliters

3. If you are treating glaucoma with topical medications, which anterior segment condition is most likely to result?*

A - Keratoconus

B - Fuchs Dystrophy

C - Ocular surface disease

D - Pterygium

4. The innate, adaptive, and complement systems are all parts of:*

A - Digestive system

B - Immune system

C - Circulatory system

D - Skeletal system

5. One of the best techniques or instruments to follow or management geographic atrophy is:*

A - Ocular response analyzer (ORA)

B - Cornea topography

C - Fundus autofluorescence (FAF)

D - OCT evaluation of the ganglion cell complex (GCC) and retina Nerve Fiber Layer (RNFL)

6. In February 2023, the FDA approved the first Treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). This pharmaceutical agent is:*

A - Syfovre (pegcetacoplan)

B - Eylea (aflibercept)

C - Vabysmo (faricimab-svoa)

D - Xdemvy (lotilaner ophthalmic solution) 0.25%

7. Syfovre’s (pegcetacoplan) mechanism of action is regulating excessive activation of the complement cascade. Which part of the complement system is it inhibiting?*

A - C1

B - C2

C - C3

D - C10

8. Izervay (avacincaptad pegol intravitreal solution) is FDA indicated for which ocular condition?*

A - Keratoconus

B - Vitreous floaters

C - Glaucoma

D - Geographic atrophy (AMD)

9. Izervay’s (avacincaptad pegol intravitreal solution) mechanism of action is regulating excessive activation of the complement cascade. Which part of the complement system is it inhibiting?*

A - C1

B - C2

C - C5

D - C10

10. Which medication is the biosimilar to Eylea (aflibercept)?*

A - Avastin

B - Pavblu

C - Lucentis

D - Vabysmo

11. Which pharmaceutical has a mechanism of action that inhibits vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) for the treatment of wet AMD or diabetic macular edema (DME)?*

A - Xdemvy (lotilaner ophthalmic solution) 0.25%

B - Miebo (perfluorohexyloctane ophthalmic solution) 100%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Vabysmo (faricimab-svoa)

12. Which biologic drug is an injection and is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)? It offered a 3-month dosing schedule in the first year of treatment but was associated with adverse intraocular inflammatory events.*

A - Bevacizumab (Avastin)

B - Ranibizumab (Lucentis)

C - Aflibercept (Eylea)

D - Brolucizumab-dbll (Beovu)

13. Which pharmaceutical agent was approved on July 25, 2023, by the FDA to treat Demodex blepharitis?*

A - Xdemvy (lotilaner ophthalmic solution) 0.25%

B - Miebo (perfluorohexyloctane ophthalmic solution) 100%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Iyuzeh (latanoprost ophthalmic solution) 0.005%

14. Which pharmaceutical agent works as an antiparasitic agent to target parasite-specific GABA-Chloride (Cl) channels?*

A - Miebo (perfluorohexyloctane ophthalmic solution) 100%

B - Xdemvy (lotilaner ophthalmic solution) 0.25%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Iyuzeh (latanoprost ophthalmic solution) 0.005%

15. Regarding the Lacrimal Functional Unit (LFU), which cranial nerve is part of the lacrimal functional unit (LFU)?*

A - Cranial nerve II – Optic nerve

B - Cranial nerve III – Oculomotor nerve

C - Cranial nerve V – Trigeminal nerve

D - Cranial nerve VI – Abducens nerve

16. Which pharmaceutical agent is a neuromodulator that stimulates the Transient Receptor Potential Melastatin 8 (TRPM8) receptor for the treatment of dry eye disease?*

A - Xdemvy (lotilaner ophthalmic solution) 0.25%

B - Vizz (aceclidine ophthalmic solution) 1.44%

C - Miebo (perfluorohexyloctane ophthalmic solution) 100%

D - Tryptyr (acoltremon ophthalmic solution) 0.003%

17. Which pharmaceutical agent, approved by the FDA on May 18, 2023, is indicated for the treatment of the signs and symptoms of dry eye disease and is water-free, preservative-free, and composed of 100% medication?*

A - Xdemvy (lotilaner ophthalmic solution)

B - Miebo (perfluorohexyloctane ophthalmic solution)

C - Qlosi (pilocarpine hydrochloride ophthalmic solution)

D - Iyuzeh (latanoprost ophthalmic solution)

18. Which pharmaceutical was approved in October 2023, by the FDA to treat the signs and symptoms of presbyopia?*

A - Xdemvy (lotilaner ophthalmic solution) 0.25%

B - Miebo (perfluorohexyloctane ophthalmic solution) 100%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Iyuzeh (latanoprost ophthalmic solution) 0.005%

19. Which presbyopia treatment is non-pilocarpine-based and is associated with minimal to no ciliary body stimulation?*

A - Vuity

B - Qlosi

C - Brimochol

D - Vizz

20. Which biologic agent used in folate receptor–alpha (FR-α)–positive platinum-resistant ovarian cancer requires clearance and ongoing monitoring by an eye care physician due to risks of superficial keratopathy, corneal deposits, and keratitis?*

A - Cenegermin-bkbj (Oxervate)

B - Teprotumumab-trbw (Tepezza)

C - Mirvetuximab Soravtansine (Elahere)

D - Tocilizumab (Actemra)

Personal Information

Name*

First Last

Email*

Phone*

OE Tracker #

License #

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Payment Information

Promotional Code

Amsterdam 2026 - Pharmaceutical Update Innovations and Insights for Eye Care*

After 90 days, pricing will increase to $30.

Price:

Retake Discount

Price:

Promotional Discount

Price:

Credit Card*

This field is hidden when viewing the form

Course Name (HIDDEN)

This field is hidden when viewing the form

Retake Code (HIDDEN)

This field is hidden when viewing the form

Quiz URL (HIDDEN)

Do not include ending backslash (aka no .com/)

This field is hidden when viewing the form

CE Hours

TQ Quiz | Pharmaceutical Update Innovations and Insights for Eye Care (Amsterdam 2026)

Quiz

Personal Information

Payment Information

Submit a Comment Cancel reply

Upcoming Conferences

Case Challenges

Case Challenges

TQ Quiz | Pharmaceutical Update Innovations and Insights for Eye Care (Amsterdam 2026)

Quiz

Personal Information

Payment Information

Submit a Comment Cancel reply

Upcoming Conferences

Case Challenges

Case Challenges

Subscribe For Event Updates